Text Size: A- A+ Facebook Twitter LinkedIn YouTube

Breaking News

Pledge the Gift of Life

Each year, the lives of thousands of people across the country are saved because someone made the choice to become an organ donor. In April, Allegheny Health Network is honored to celebrate National Donate Life Month and pay tribute to all of those who have bestowed the precious gift of life to another through organ donation. Visit AHNdonate.org to learn more and register to be an organ donor.



Format: 04/23/2014
Format: 04/23/2014


Allegheny General Hospital Joins International Study to Determine if Progesterone Could Reduce Brain Damage and Death from Traumatic Brain Injury

Tuesday, January 18th, 2011

Investigators from the Neurosciences Institute at Allegheny General Hospital (AGH) are participating in a research study sponsored by BHR Pharma, LLC to determine whether the hormone progesterone may aid in recovery following a severe (GCS 4-8) Traumatic Brain Injury (TBI).

The SyNAPSe? (Study of the Neuroprotective Activity of Progesterone in Severe traumatic brain injuries) study will enroll 1,180 patients from approximately 100 medical centers worldwide to see if previously determined benefits of using progesterone to treat TBI are more likely to be seen if treatment is given within eight hours.

“No new treatments for TBI have been discovered in decades,” said Jack Wilberger, MD, Chairman of the Department of Neurosurgery at Allegheny General Hospital and principal investigator for the SyNAPSe trial at AGH. “This trial may yield the first-ever FDA-approved medical treatment for severe TBI and greatly impact patients’ ability to heal from these devastating injuries.”

Traumatic brain injury is the leading cause of death and disability in children and young adults. According to the Centers for Disease Control, more than 1.5 million Americans suffer TBI each year, more than 50,000 of whom die. Brain injury may occur whenever there is a blow to the head, whether or not the skull is fractured and can cause severe disability, including coma, paralysis and death; as well as delayed symptoms such as headaches, memory problems, mood changes, sleeping issues and altering of the senses.

Current treatment for TBI involves maintaining blood pressure and oxygenation while controlling intracranial pressure. Treatment that starts within the first hours after injury is crucial to prevent further brain damage.

Previous studies have indicated that progesterone serves as a brain protector, promoting the repair of the brain after TBI by decreasing brain swelling. Progesterone occurs naturally in both men and women, although it is best known as a female hormone responsible for maintaining pregnancies.

A 100-patient pilot study of progesterone treatment for TBI conducted at Emory University revealed not only that progesterone has no serious side effects, but also that patients with severe TBI that were given the hormone were half as likely to die as those who received placebo. In the Emory study, 13 percent of patients who received progesterone died, while 30 percent of patients receiving placebo died. In patients who had moderate brain injuries, those receiving progesterone were less profoundly disabled.

The SyNAPSe trial will further examine the benefits of administering progesterone and determine if additional benefits may be achieved when the drug is administered quickly. Patients enrolled in the SyNAPSe trial must start progesterone infusion within eight hours of their TBI.

“With head trauma, quick intervention has always been the key,” Dr. Wilberger said. “This trial will help to define the benefits of early intervention with progesterone and could result in a new standard of care for patients with severe TBI.”

Allegheny General Hospital is actively considering patients for enrollment in the SyNAPSe trial over the next several months.

The Neuroscience Program at AGH integrates world-renowned experts in the subspecialties of neurology, neurotology, neuroradiology, neuro-critical care, and neurosurgery to offer world class care for patients with the most complex neurological disorders. Recognized as both a Neurosciences Center of Excellence and a Spine Center of Excellence, the program serves as a national and international referral center for treatment of all types of neurological conditions.

West Penn Allegheny Health System
Tell us who you are:

What areas do you use on our website?*
(select more than one if it applies)

Did you find what you were looking for?

Would you refer others to our website?

Can we contact you for future questions?

CAPTCHA math question:* 7 + 7 =

Thank you for completing the West Penn Allegheny Health System website survey.
We value your feedback and comments.